BOSTON, July 27, 2026
HoneyNaps has officially registered as a Contract Research Organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT), marking a significant milestone in the company’s strategy to expand AI-powered clinical trial analytics for global pharmaceutical, medical device, and healthcare organizations. The registration strengthens HoneyNaps’ ability to provide standardized sleep data analysis services while accelerating the commercialization of SOMNUM Clinical, its advanced artificial intelligence platform for clinical research. Built on the company’s FDA-cleared SOMNUM AI technology, the platform automatically analyzes polysomnography (PSG) data and delivers quantitative measurements of critical sleep parameters, including sleep stages, apnea-hypopnea index (AHI), arousal events, and other clinically relevant biomarkers. With experience supporting more than 10,000 clinical research participants and managing multicenter studies, HoneyNaps aims to position itself as a global leader in digital biomarker analytics, helping sponsors improve trial efficiency, data quality, and decision-making across diverse therapeutic areas.
AI Platform Enhances Sleep Data Analysis for Clinical Research
The launch of SOMNUM Clinical represents HoneyNaps’ next step in applying artificial intelligence to streamline one of the most resource-intensive aspects of sleep-related clinical trials. Traditionally, analysis of polysomnography (PSG) recordings requires extensive manual review by trained specialists, creating delays and variability across study sites. HoneyNaps’ AI-powered platform automates this process using FDA-cleared SOMNUM AI, reducing analysis time by more than 90% while maintaining standardized scoring based on American Academy of Sleep Medicine (AASM) guidelines. By automatically evaluating sleep architecture, respiratory events, and additional physiological metrics, the platform provides objective and reproducible results suitable for multicenter global clinical trials. The automation not only improves operational efficiency but also minimizes inter-site and inter-scorer variability, helping sponsors generate higher-quality clinical data for regulatory submissions and product development.
Digital Biomarkers Support Expanding Clinical Trial Applications
As recognition of sleep as a digital biomarker continues to grow, HoneyNaps is expanding its services beyond traditional sleep disorder research into broader therapeutic areas. Sleep analysis is increasingly being incorporated into clinical studies involving obesity, cardiovascular disease, neurodegenerative disorders, mental health, pharmaceuticals, medical devices, digital therapeutics (DTx), and wearable technologies. Through its newly established CRO capabilities, HoneyNaps will combine advanced AI analytics with comprehensive clinical trial support, enabling sponsors to integrate standardized sleep measurements into complex research programs. The company believes objective sleep metrics can provide valuable insights into treatment response, disease progression, and patient outcomes, making them increasingly important endpoints in modern clinical development. By leveraging artificial intelligence alongside extensive clinical operations experience, HoneyNaps aims to accelerate trial timelines while improving data consistency across international research programs.
Advertisement
Growing Market Drives Demand for AI-Powered Clinical Analytics
HoneyNaps’ CRO registration comes as demand for AI-enabled clinical trial technologies continues to increase across the global healthcare industry. The company cites strong market growth in clinical sleep research, driven by rising interest in digital health, precision medicine, and biomarker-based clinical development. Having already contributed to studies involving more than 10,000 participants, HoneyNaps is positioned to support pharmaceutical companies, biotechnology firms, medical device manufacturers, and digital health innovators seeking advanced analytical solutions for complex clinical trials. By combining FDA-cleared AI technology, standardized clinical workflows, and specialized expertise in sleep medicine, the company aims to improve research efficiency while enabling more reliable clinical evidence generation. The milestone further strengthens HoneyNaps’ position in the evolving field of AI-powered clinical research, where automation and digital biomarkers are becoming increasingly important for accelerating the development of next-generation healthcare innovations.
Source: HoneyNaps press release
